Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.

MLA

Urman, Robert, et al. “Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.” Pain & Therapy, vol. 13, no. 5, Oct. 2024, pp. 1299–313. EBSCOhost, https://doi.org/10.1007/s40122-024-00644-z.

APA

Urman, R., Princic, N., Vuvu, F., Patel, L. B., Oh, S., Chandler, D., Hindiyeh, N., & Bensink, M. E. (2024). Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis. Pain & Therapy, 13(5), 1299–1313. https://doi.org/10.1007/s40122-024-00644-z

Chicago

Urman, Robert, Nicole Princic, Fiston Vuvu, Leah B. Patel, Sam Oh, David Chandler, Nada Hindiyeh, and Mark E. Bensink. 2024. “Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis.” Pain & Therapy 13 (5): 1299–1313. doi:10.1007/s40122-024-00644-z.